TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18957134

Group type: EXPERIMENTAL
Intervention: high-phospholipid, high-PE lipid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: high-phospholipid, medium-PE lipid
Number of subjects: 18

Group type: COMPARATOR
Intervention: no-phospholipid, no-PE control lipid
Number of subjects: 18

Group type: COMPARATOR
Intervention: water control
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: medium-PE lipid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: high-PE lipid
Number of subjects: 18
Study: 16884341

Group type: EXPERIMENTAL
Intervention: Massage therapy (twice weekly for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (friendly visit, twice weekly for 12 weeks)
Number of subjects: 0
Study: 12828227

Group type: EXPERIMENTAL
Intervention: Fluvastatin started immediately after PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11073858

Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy from fat)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-fat diet (5% of energy from fat)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 30
Study: 8841224

Group type: EXPERIMENTAL
Intervention: One E2 transdermal system
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Two E2 transdermal systems
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo transdermal system
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: E2 transdermal system
Number of subjects: 324
Study: 1640953

Group type: EXPERIMENTAL
Intervention: Methylprednisolone and chlorambucil for six months (group 1)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Methylprednisolone alone for six months (group 2)
Number of subjects: 92
Study: 6383908

Group type: EXPERIMENTAL
Intervention: i.v. group (insulin by continuous intravenous infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: s.c. group (conventional subcutaneous therapy)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: i.v. group
Number of subjects: 14

Group type: COMPARATOR
Intervention: s.c. group
Number of subjects: 14
Study: 29525768

Group type: EXPERIMENTAL
Intervention: Usual care plus an internet intervention (SupportBack)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Usual care plus an internet intervention with additional physiotherapist telephone support
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Usual care plus an internet intervention
Number of subjects: 87
Study: 27210863

Group type: EXPERIMENTAL
Intervention: Stabilization exercise (SE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine physiotherapy (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 25212990

Group type: EXPERIMENTAL
Intervention: Tourniquet used throughout the surgical procedure (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Limited use of tourniquet starting from cementation to completion (Group B)
Number of subjects: 60
Study: 22466349

Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg twice daily for 5 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Estradiol (100-μg patch daily for 5 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Hypogonadism (after 3 months of Lupron)
Number of subjects: 43
Study: 20227097

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retention sutured sequential fascial closure (RSSFC)
Number of subjects: 30
Study: 18709009

Group type: EXPERIMENTAL
Intervention: Amnioplasty using amnion membrane conserved in 76% alcohol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (exposition, occlusive dressing, initial excision with skin grafting)
Number of subjects: 60
Study: 15753413

Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIG) 0.4 g/kg body weight, administered at days 0, 1, 2, 30, and 60
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 68
Study: 12509314

Group type: EXPERIMENTAL
Intervention: ICD-10 Primary Health Care Guidelines for Diagnosis and Management of Mental Disorders
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 10497961

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alprazolam (a tranquillizer)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9091853

Group type: COMPARATOR
Intervention: Glycogen concentration in neutrophils in diabetics
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Glycogen contents in neutrophils in IDDM patients
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Glycogen contents in neutrophils in NIDDM patients
Number of subjects: 64
Study: 2003051

Group type: EXPERIMENTAL
Intervention: Ventilating tube insertion
Number of subjects: 57

Group type: COMPARATOR
Intervention: Myringotomy alone or no surgery (Control)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 57
Study: 6353396

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 0
Study: 31711059

Group type: EXPERIMENTAL
Intervention: Circulating levels of uric acid
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Genotypes of rs11722228
Number of subjects: 989
Study: 31752833

Group type: EXPERIMENTAL
Intervention: Smart phone application for continuing medical education (CME)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Booklet, CME seminar, and pamphlet (Control)
Number of subjects: 107
Study: 30295338

Group type: EXPERIMENTAL
Intervention: Alteplase plus fingolimod
Number of subjects: 46

Group type: COMPARATOR
Intervention: Alteplase alone
Number of subjects: 46
Study: 27822028

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 30
Study: 25270861

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 160

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 160
Study: 22363556

Group type: EXPERIMENTAL
Intervention: High altitude exposure (3700 m) for 50 days
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Return to low altitude (1500 m) after 50 days
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (low altitude)
Number of subjects: 194
Study: 19648220

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17942389

Group type: EXPERIMENTAL
Intervention: Email notifications about a nutrition education website sent over a period of 4 months (up to 4 messages).
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Responders to email notifications.
Number of subjects: 755

Group type: COMPARATOR
Intervention: Nonresponders to email notifications.
Number of subjects: 755
Study: 15962680

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo (tetanus toxoid)
Number of subjects: 635
Study: 12541005

Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Local services only
Number of subjects: 24
Study: 10729668

Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 36
Study: 8971505

Group type: EXPERIMENTAL
Intervention: External beam radiation to the mediastinum (50‐56 Gy, 8 or 23 MeV photons, 2 Gy/day, 5 days a week) starting 4 weeks after the operation.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no further oncologic treatment).
Number of subjects: 155
Study: 1309083

Group type: EXPERIMENTAL
Intervention: Computer-assisted communication of medical information between the chronic care patient and the physician
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 3981628

Group type: EXPERIMENTAL
Intervention: Stress management treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Brief consultation program
Number of subjects: 12
Study: 30803493

Group type: EXPERIMENTAL
Intervention: 3% potassium nitrate (KNO3) mouthrinse plus fluoride toothpaste
Number of subjects: 191

Group type: COMPARATOR
Intervention: Fluoride toothpaste alone
Number of subjects: 191
Study: 30033477

Group type: EXPERIMENTAL
Intervention: Digital platform-based implementation strategy for 12 months
Number of subjects: 473

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 473
Study: 27206648

Group type: EXPERIMENTAL
Intervention: High-frequency sampling (cohorts 1-3)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ibuprofen pretreatment (800 mg) before catheterization (cohort 3)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Optimized low-frequency sampling protocol (cohort 4)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (cohort 2; sampling started 6 h post catheterization)
Number of subjects: 18
Study: 24602579

Group type: EXPERIMENTAL
Intervention: Facilitated video curriculum on social determinants of health (SDH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no video curriculum)
Number of subjects: 100
Study: 22126622

Group type: EXPERIMENTAL
Intervention: Oral health education program targeting oral malodor prevention
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (Grade 2 students)
Number of subjects: 298
Study: 20123877

Group type: EXPERIMENTAL
Intervention: Extraoral infraorbital nerve block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intraoral infraorbital nerve block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40
Study: 17398191

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no antihypertensive therapy)
Number of subjects: 0
Study: 15723895

Group type: EXPERIMENTAL
Intervention: UCL diabetes self-management programme (UCL-DSMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12120905

Group type: COMPARATOR
Intervention: Methotrexate once weekly
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Methotrexate twice weekly
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (once weekly and twice weekly)
Number of subjects: 80
Study: 10451039

Group type: EXPERIMENTAL
Intervention: Eprosartan 400 mg total daily dose (b.i.d.), increased to 600 and 800 mg if necessary
Number of subjects: 118

Group type: COMPARATOR
Intervention: Enalapril 10 mg total daily dose (o.d.), increased to 20 and 40 mg if necessary
Number of subjects: 118
Study: 12879543

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clotrimazole and Ketoconazole
Number of subjects: 0
Study: 2190975

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate
Number of subjects: 74
Study: 30876403

Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderating factors
Number of subjects: 0
Study: 28652463

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Homeostasis model of insulin resistance
Number of subjects: 503
Study: 25872567

Group type: EXPERIMENTAL
Intervention: Daily oral curcumin at the target dose determined in Phase I
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard care oxaliplatin-based chemotherapy alone
Number of subjects: 33
Study: 23081732

Group type: EXPERIMENTAL
Intervention: BB genotype
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ff genotype
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bsm1 genotype
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fok1 genotype
Number of subjects: 120
Study: 21429609

Group type: EXPERIMENTAL
Intervention: Accelerated fractionated radiotherapy (6Fx/week)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Accelerated fractionated radiotherapy
Number of subjects: 794

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 794
Study: 19306822

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 308

Group type: COMPARATOR
Intervention: No gastric bypass (control group)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Population-based obese individuals (control group)
Number of subjects: 308
Study: 16394212

Group type: EXPERIMENTAL
Intervention: e-mediated communication with doctors
Number of subjects: 0
Study: 15233827

Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (N)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK)
Number of subjects: 99
Study: 11257245

Group type: EXPERIMENTAL
Intervention: eZ.on condom
Number of subjects: 360

Group type: COMPARATOR
Intervention: latex condom
Number of subjects: 360
Study: 9159629

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (750 IU per day for 7 to 10 days) and ascorbic acid (1 gm 12 hours before operation)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol and ascorbic acid
Number of subjects: 76
Study: 8205297

Group type: EXPERIMENTAL
Intervention: Isradipine + Captopril
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo + Captopril
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Methyldopa + Captopril
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: QoL Assessment
Number of subjects: 368
Study: 3581681

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 40
Study: 29952809

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation plus Oral Nutritional Supplement (PRONS) for 12 weeks
Number of subjects: 30
Study: 27601237

Group type: EXPERIMENTAL
Intervention: Afatinib 30 mg
Number of subjects: 468

Group type: COMPARATOR
Intervention: Afatinib 40 mg
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Dose reduction within the first 6 months
Number of subjects: 468

Group type: COMPARATOR
Intervention: No dose reduction within the first 6 months
Number of subjects: 468
Study: 24709304

Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Plate fixation
Number of subjects: 71
Study: 22497024

Group type: EXPERIMENTAL
Intervention: External stent drainage of the pancreatic duct (stented group)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No external stent drainage of the pancreatic duct (non-stented group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: External stent drainage of the pancreatic duct (stented group) among patients with non-dilated duct
Number of subjects: 93

Group type: COMPARATOR
Intervention: No external stent drainage of the pancreatic duct (non-stented group) among patients with non-dilated duct
Number of subjects: 93
Study: 21111098

Group type: EXPERIMENTAL
Intervention: Peer eating a large amount of breakfast
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Peer eating a small amount of breakfast
Number of subjects: 57

Group type: COMPARATOR
Intervention: Peer eating nothing
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Small-Breakfast condition
Number of subjects: 57
Study: 18496149

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (1 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 16083921

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin) treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study: 12679222

Group type: EXPERIMENTAL
Intervention: S 18886 (10 mg single oral dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10383501

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: H. pylori eradication
Number of subjects: 41
Study: 8893888

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 1856813

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 23
Study: 6137969

Group type: EXPERIMENTAL
Intervention: Midazolam 0.07 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 0.10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31347931

Group type: EXPERIMENTAL
Intervention: Nonaction adaptive videogames (Lumosity), 10 games, 15 sessions of 30 minutes each
Number of subjects: 48

Group type: COMPARATOR
Intervention: Active control group played two nonadaptive simulation-strategy games (SimCity and The Sims), 15 sessions of 30 minutes each
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 48
Study: 30594229

Group type: EXPERIMENTAL
Intervention: Pegloticase treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 87
Study: 25850440

Group type: EXPERIMENTAL
Intervention: Caffeinated espresso
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Decaffeinated espresso
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Warm water
Number of subjects: 77
Study: 24649935

Group type: EXPERIMENTAL
Intervention: 830 nm low-level laser therapy (LLLT) administered five times per week for 2 weeks (average power 60 mW, peak power 8 W, 10 Hz, 600 sec, and 9.7 J/cm² per fracture site)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo group received sham laser treatment
Number of subjects: 50
Study: 22647618

Group type: EXPERIMENTAL
Intervention: Urinary parameters of pyridoxal‐phosphate (PLP)‐dependent tryptophan degradation and the level of 4‐pyridoxic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ratio of 4‐pyridoxic acid to kynurenine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ratio of 3‐hydroxyanthranilic acid to 3‐hydroxykynurenine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PLP-dependent disturbances of tryptophan metabolism
Number of subjects: 0
Study: 20435260

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study: 17852064

Group type: EXPERIMENTAL
Intervention: Stop Using Stuff (SUS) - a brief cognitive behavioural therapy (CBT) intervention, 4 to 6 sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study: 17127477

Group type: EXPERIMENTAL
Intervention: Low-glycaemic-index (LGI) diet
Number of subjects: 10
Study: 12206443

Group type: EXPERIMENTAL
Intervention: 9-month exercise intervention (goal: at least 10 miles of weekly brisk walking or jogging)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Baseline exercise motivational readiness stage
Number of subjects: 342
Study: 15510439

Group type: EXPERIMENTAL
Intervention: Whole-word method
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subword method
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined whole-word and subword method
Number of subjects: 48
Study: 7550800

Group type: EXPERIMENTAL
Intervention: Intervention workwear (new coverall, shirt, trousers, underwear, socks, and boots)
Number of subjects: 10
Study: 1657656

Group type: EXPERIMENTAL
Intervention: 10.5 g/day dietary fibre
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 21 g/day dietary fibre
Number of subjects: 10

Group type: COMPARATOR
Intervention: fibre‐free diet
Number of subjects: 10
Study: 7117309

Group type: EXPERIMENTAL
Intervention: L-dopa and/or physostigmine treatment
Number of subjects: 45
Study: 31928229

Group type: EXPERIMENTAL
Intervention: Genotyped group (CYP2C19 genotyping via salivary swab)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Usual care group (no genotyping)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Genotyped group (CYP2C19 genotyping)
Number of subjects: 504
Study: 30357263

Group type: EXPERIMENTAL
Intervention: DHA+AA (200 mg DHA and 200 mg AA daily for 6 months)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo (microencapsulated corn oil)
Number of subjects: 377
Study: 27693978

Group type: EXPERIMENTAL
Intervention: Verum acupuncture plus fluoxetine (n=22)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham acupuncture plus fluoxetine (n=24)
Number of subjects: 46
Study: 25527480

Group type: EXPERIMENTAL
Intervention: Walking at slow speed (100 m)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Walking at medium speed (100 m)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Walking at fast speed (100 m)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Awkward carry (13.6 kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Side carry (13.6 kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Front carry (13.6 kg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Carry-in-backpack (13.6 kg)
Number of subjects: 46
Study: 23949801

Group type: EXPERIMENTAL
Intervention: Low-glucose regimen (combination of dextrose-based solution, icodextrin and amino acids)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Dextrose solutions only (control group)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Low-glucose regimen (intervention group)
Number of subjects: 251